COMPLETED

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a Phase 1 study to assess the safety and clinical activity of RO7623066 alone and in combination in patients with advanced solid tumors.

Official Title

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

Quick Facts

Study Start:2021-08-26

Study Completion:2025-11-26

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT05240898

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Age 18 years or older 2. Life expectancy of ≥ 12 weeks 3. Measurable disease or non-measurable disease per RECIST v1.1 in dose escalation and the Food Effect Cohort only; patients in dose expansion and Backfill Cohorts are required to have measurable disease per RECIST v1.1 4. Recovered to ≤ Grade 1 or baseline toxicity (except alopecia) from prior therapy (per NCI-CTCAE v5.0) 5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 6. Adequate bone marrow function defined as: 1. absolute neutrophil count of ≥ 1.5 × 109/L 2. platelet count of ≥ 100.0 × 109/L 3. hemoglobin of ≥ 10.0 g/dL (with or without transfusion) 7. Adequate renal function defined as calculated creatinine clearance (Cockcroft- Gault) ≥ 40 mL/min for patients with creatinine levels above institutional normal 8. Adequate hepatic function defined as: 1. Total bilirubin ≤ 1.5 × upper limit of normal (ULN) unless associated with Gilbert's syndrome 2. Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases) 9. Female patients who are women of childbearing potential (WOCP) (defined as physiologically and anatomically capable of becoming pregnant), confirmed of a negative pregnancy test and agreement to the use of a highly effective contraceptive method or at least 2 effective methods at the same time during study treatment period and for up to 3 months after the last dose of study treatment. Male patients must be willing to use effective barrier contraception (ie, condoms) during the study treatment period and for up 3 months after the last dose of study treatment 10. Capable of understanding and complying with protocol requirements 11. Signed and dated institutional review board (IRB)/independent ethics committee (IEC) approved informed consent form (ICF) before any protocol-directed Screening procedures are performed 12. Does not require ongoing treatment with strong or moderate CYP3A4 inhibitors or inducers. 13. Histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumors who meet one of the following criteria (dose escalation only): 1. Relapsed or progressed through standard therapy 2. Have a disease for which no standard effective therapy exists 3. Not a candidate for standard effective therapy Note: In men with prostate cancer, baseline testosterone levels must also be ≤ 50 ng/dL (≤ 2.0 nM) and surgical or ongoing medical castration must be maintained throughout the duration of the study	1. Prior anticancer treatment including: 1. Chemotherapy or small molecule-targeted therapy \< 2 weeks prior to first dose of study treatment 2. Any antibody therapy \< 5 half-lives from first dose of study treatment (or 4 weeks since last therapy, whichever is the shortest) 3. Programmed cell death protein-1 or programmed cell death ligand 1 inhibitor therapy \< 4 weeks from first dose of study treatment 4. Invasive surgery requiring general anesthesia \< 30 days from first dose of study treatment 5. Chemotherapy with nitrosoureas or mitomycin C \< 45 days from first dose of study treatment 6. Radiation therapy (including radiofrequency ablation) \< 4 weeks prior to initiation of study treatment Note: Prior stereotactic body radiation therapy or local palliative radiation is allowed \< 2 weeks prior to first dose of study treatment 2. Ongoing Grade 2 or greater toxicity, except alopecia, related to any prior treatment (ie, chemotherapy, targeted therapy, radiation, or surgery) 3. Prolongation of QT/QTc interval (QTc interval \> 480 msec) using the Frederica method of QTc analysis 4. Women who are pregnant or nursing 5. Seropositive for human immunodeficiency virus (HIV) 1 or 2 or acquired immunodeficiency syndrome or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) (Note: Patients with positive HCV antibody may be eligible if HCV ribonucleic acid \[RNA\] is undetectable on a quantitative HCV RNA assay, the Medical Monitor is available for advice) 6. Primary malignant brain tumor 7. Symptomatic and/or untreated brain metastases, active leptomeningeal disease, or central nervous system malignant disease requiring steroids or other therapeutic intervention Note: Patients with definitively treated brain metastases will be considered for enrollment after seeking advice from the Medical Monitor and must be clinically stable for ≥ 2 weeks prior to the start of treatment 8. Previous solid organ or hematopoietic cell transplant 9. Need for treatment with steroids at stable doses (\> 10 mg prednisone or equivalent per day). Note: Oral steroids up to 10 mg/day, topical, ophthalmic, or inhaled steroid medications are allowed 10. Uncontrolled hypertension \> 150/100 mm Hg despite aggressive therapy 11. Concurrent participation in any other investigational therapeutic study 12. History of stroke, transient ischemic attack, unstable angina, or myocardial infarction within 3 months prior to first dose of study treatment 13. Unable to swallow whole tablets or capsules. Nasogastric or gastric-tube (G-tube)administration is not allowed 14. GI disease that would impair ability to swallow, retain, or absorb drug is not allowed 15. Uncontrolled concurrent disease or illness including but not limited to: 1. Symptomatic congestive heart failure according to New York Heart Association (NYHA) classification, Class III or IV (per NYHA Classification) unstable angina pectoris, or clinically significant cardia arrhythmia 2. Diabetes mellitus (ie, fasting blood glucose \> 220 despite acceptable chronic diabetes therapy) 3. Psychiatric illness that would limit compliance with study requirements, as determined by the Investigator 16. Other severe, acute, or chronic medical condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or that may interfere with the interpretation of the study results, and in the judgment of the Investigator, would make the patient inappropriate for the study 17. Known hypersensitivity to any component of RO7623066 or excipient 18. History of and/or ongoing adrenal disorder (eg, Cushing's disease, Addison's disease, adrenal gland suppression) 19. Suspected pneumonitis or interstitial lung disease (confirmed radiography or by computed tomography \[CT\]) or a history of pneumonitis or interstitial lung disease in the last 6 months 20. Known additional malignancy that is active and/or progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, or other cancer for which the patient has been disease-free for at least 2 years 21. Myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), or baseline features suggestive of MDS or AML on peripheral blood smear or bone marrow biopsy 22. Treatment with strong or moderate CYP3A4 inhibitors or inducers for a period of 5 half-lives of the inhibitor or inducer prior to the first dose of RO7623066. 23. Blood transfusions within 4 weeks prior to Screening

Inclusion Criteria

Exclusion Criteria

1. Age 18 years or older
2. Life expectancy of ≥ 12 weeks
3. Measurable disease or non-measurable disease per RECIST v1.1 in dose escalation and the Food Effect Cohort only; patients in dose expansion and Backfill Cohorts are required to have measurable disease per RECIST v1.1
4. Recovered to ≤ Grade 1 or baseline toxicity (except alopecia) from prior therapy (per NCI-CTCAE v5.0)
5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
6. Adequate bone marrow function defined as:
1. absolute neutrophil count of ≥ 1.5 × 109/L
2. platelet count of ≥ 100.0 × 109/L
3. hemoglobin of ≥ 10.0 g/dL (with or without transfusion)
7. Adequate renal function defined as calculated creatinine clearance (Cockcroft- Gault) ≥ 40 mL/min for patients with creatinine levels above institutional normal
8. Adequate hepatic function defined as:
1. Total bilirubin ≤ 1.5 × upper limit of normal (ULN) unless associated with Gilbert's syndrome
2. Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases)
9. Female patients who are women of childbearing potential (WOCP) (defined as physiologically and anatomically capable of becoming pregnant), confirmed of a negative pregnancy test and agreement to the use of a highly effective contraceptive method or at least 2 effective methods at the same time during study treatment period and for up to 3 months after the last dose of study treatment. Male patients must be willing to use effective barrier contraception (ie, condoms) during the study treatment period and for up 3 months after the last dose of study treatment
10. Capable of understanding and complying with protocol requirements
11. Signed and dated institutional review board (IRB)/independent ethics committee (IEC) approved informed consent form (ICF) before any protocol-directed Screening procedures are performed
12. Does not require ongoing treatment with strong or moderate CYP3A4 inhibitors or inducers.
13. Histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumors who meet one of the following criteria (dose escalation only):
1. Relapsed or progressed through standard therapy
2. Have a disease for which no standard effective therapy exists
3. Not a candidate for standard effective therapy Note: In men with prostate cancer, baseline testosterone levels must also be ≤ 50 ng/dL (≤ 2.0 nM) and surgical or ongoing medical castration must be maintained throughout the duration of the study

1. Prior anticancer treatment including:
1. Chemotherapy or small molecule-targeted therapy \< 2 weeks prior to first dose of study treatment
2. Any antibody therapy \< 5 half-lives from first dose of study treatment (or 4 weeks since last therapy, whichever is the shortest)
3. Programmed cell death protein-1 or programmed cell death ligand 1 inhibitor therapy \< 4 weeks from first dose of study treatment
4. Invasive surgery requiring general anesthesia \< 30 days from first dose of study treatment
5. Chemotherapy with nitrosoureas or mitomycin C \< 45 days from first dose of study treatment
6. Radiation therapy (including radiofrequency ablation) \< 4 weeks prior to initiation of study treatment Note: Prior stereotactic body radiation therapy or local palliative radiation is allowed \< 2 weeks prior to first dose of study treatment
2. Ongoing Grade 2 or greater toxicity, except alopecia, related to any prior treatment (ie, chemotherapy, targeted therapy, radiation, or surgery)
3. Prolongation of QT/QTc interval (QTc interval \> 480 msec) using the Frederica method of QTc analysis
4. Women who are pregnant or nursing
5. Seropositive for human immunodeficiency virus (HIV) 1 or 2 or acquired immunodeficiency syndrome or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) (Note: Patients with positive HCV antibody may be eligible if HCV ribonucleic acid \[RNA\] is undetectable on a quantitative HCV RNA assay, the Medical Monitor is available for advice)
6. Primary malignant brain tumor
7. Symptomatic and/or untreated brain metastases, active leptomeningeal disease, or central nervous system malignant disease requiring steroids or other therapeutic intervention Note: Patients with definitively treated brain metastases will be considered for enrollment after seeking advice from the Medical Monitor and must be clinically stable for ≥ 2 weeks prior to the start of treatment
8. Previous solid organ or hematopoietic cell transplant
9. Need for treatment with steroids at stable doses (\> 10 mg prednisone or equivalent per day). Note: Oral steroids up to 10 mg/day, topical, ophthalmic, or inhaled steroid medications are allowed
10. Uncontrolled hypertension \> 150/100 mm Hg despite aggressive therapy
11. Concurrent participation in any other investigational therapeutic study
12. History of stroke, transient ischemic attack, unstable angina, or myocardial infarction within 3 months prior to first dose of study treatment
13. Unable to swallow whole tablets or capsules. Nasogastric or gastric-tube (G-tube)administration is not allowed
14. GI disease that would impair ability to swallow, retain, or absorb drug is not allowed
15. Uncontrolled concurrent disease or illness including but not limited to:
1. Symptomatic congestive heart failure according to New York Heart Association (NYHA) classification, Class III or IV (per NYHA Classification) unstable angina pectoris, or clinically significant cardia arrhythmia
2. Diabetes mellitus (ie, fasting blood glucose \> 220 despite acceptable chronic diabetes therapy)
3. Psychiatric illness that would limit compliance with study requirements, as determined by the Investigator
16. Other severe, acute, or chronic medical condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or that may interfere with the interpretation of the study results, and in the judgment of the Investigator, would make the patient inappropriate for the study
17. Known hypersensitivity to any component of RO7623066 or excipient
18. History of and/or ongoing adrenal disorder (eg, Cushing's disease, Addison's disease, adrenal gland suppression)
19. Suspected pneumonitis or interstitial lung disease (confirmed radiography or by computed tomography \[CT\]) or a history of pneumonitis or interstitial lung disease in the last 6 months
20. Known additional malignancy that is active and/or progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, or other cancer for which the patient has been disease-free for at least 2 years
21. Myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML), or baseline features suggestive of MDS or AML on peripheral blood smear or bone marrow biopsy
22. Treatment with strong or moderate CYP3A4 inhibitors or inducers for a period of 5 half-lives of the inhibitor or inducer prior to the first dose of RO7623066.
23. Blood transfusions within 4 weeks prior to Screening

Contacts and Locations

Principal Investigator

Clinical Trials

STUDY_DIRECTOR

Hoffmann-La Roche

Study Locations (Sites)

University of California Irvine Medical Center

Orange, California, 92868

United States

Yale School of Medicine

New Haven, Connecticut, 06510-3206

United States

Barbara Ann Karmanos Cancer Institute

Detroit, Maine, 48201-2013

United States

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215

United States

South Texas Accelerated Research Therapeutics (START) - Midwest Location

Grand Rapids, Michigan, 49546

United States

Hackensack University Medical Center

Hackensack, New Jersey, 07601

United States

Cleveland Clinic,

Cleveland, Ohio, 44195

United States

The Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210

United States

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

United States

Oregon Health & Science University

Portland, Oregon, 97239

United States

Rhode Island Hospital

Providence, Rhode Island, 02906

United States

Mary Crowley Medical Research Center

Dallas, Texas, 75230

United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030-4009

United States

South Texas Accelerated Research Therapeutics (START)

San Antonio, Texas, 98229

United States

University of Virginia Health System

Charlottesville, Virginia, 22908

United States

Collaborators and Investigators

Sponsor: Hoffmann-La Roche

Clinical Trials, STUDY_DIRECTOR, Hoffmann-La Roche

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-08-26

Study Completion Date2025-11-26

Study Record Updates

Study Start Date2021-08-26

Study Completion Date2025-11-26

Terms related to this study

Additional Relevant MeSH Terms

Advanced Solid Tumors